Strategies to Overcome High-Risk Multiple Myeloma

被引：1

作者：

Sanchez, Larysa ^{[1
]}

机构：

[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Multiple Myeloma Program, New York, NY 10029 USA

来源：

CANCER JOURNAL | 2021年 / 27卷 / 03期

关键词：

High risk; high-risk myeloma; myeloma; multiple myeloma; DARATUMUMAB PLUS LENALIDOMIDE; STEM-CELL TRANSPLANTATION; OPEN-LABEL; CONSOLIDATION THERAPY; DEXAMETHASONE; BORTEZOMIB; SURVIVAL; CARFILZOMIB; PREDNISONE; MELPHALAN;

D O I：

10.1097/PPO.0000000000000529

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple myeloma (MM) patients with high-risk cytogenetics continue to have inferior outcomes despite recent advances in the treatment of MM. As defined by the International Myeloma Working Group, the presence of t(4;14), t(14;16), del(17p), t(14;20) and amplification of 1q are considered to be high-risk chromosomal abnormalities associated with poor survival. Despite the use of immunomodulatory agents, proteasome inhibitors, autologous stem cell transplantation, and anti-CD38 monoclonal antibodies, clinical trials of current therapies have not shown strong statistical evidence of being able to overcome the poor prognosis of high-risk disease. Novel treatment approaches are urgently needed to improve survival in this subset of MM patients.

引用

页码：201 / 204

页数：4

共 50 条

[21] Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents [J].

Avet-Loiseau, Herve ;

Facon, Thierry .

LEUKEMIA, 2018, 32 (06) :1267-1276

[22] Treatment options for multiple myeloma patients with high-risk disease [J].

Ailawadhi, Sikander ;

Masood, Aisha ;

Sher, Taimur ;

Miller, Kena C. ;

Wood, Margaret ;

Lee, Kelvin ;

Chanan-Khan, Asher .

MEDICAL ONCOLOGY, 2010, 27 :53-61

[23] Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma [J].

Dimopoulos, Meletios A. ;

Voorhees, Peter M. ;

Schjesvold, Fredrik ;

Cohen, Yael C. ;

Hungria, Vania ;

Sandhu, Irwindeep ;

Lindsay, Jindriska ;

Baker, Ross I. ;

Suzuki, Kenshi ;

Kosugi, Hiroshi ;

Levin, Mark-David ;

Beksac, Meral ;

Stockerl-Goldstein, Keith ;

Oriol, Albert ;

Mikala, Gabor ;

Garate, Gonzalo ;

Theunissen, Koen ;

Spicka, Ivan ;

Mylin, Anne K. ;

Bringhen, Sara ;

Uttervall, Katarina ;

Pula, Bartosz ;

Medvedova, Eva ;

Cowan, Andrew J. ;

Moreau, Philippe ;

Mateos, Maria-Victoria ;

Goldschmidt, Hartmut ;

Ahmadi, Tahamtan ;

Sha, Linlin ;

Cortoos, Annelore ;

Katz, Eva G. ;

Rousseau, Els ;

Li, Liang ;

Dennis, Robyn M. ;

Carson, Robin ;

Rajkumar, S. Vincent .

NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (18) :1777-1788

[24] Defining and treating high-risk multiple myeloma [J].

Usmani, S. Z. ;

Rodriguez-Otero, P. ;

Bhutani, M. ;

Mateos, M-V ;

Miguel, J. S. .

LEUKEMIA, 2015, 29 (11) :2119-2125

[25] Current Review on High-Risk Multiple Myeloma [J].

Henry S. H. Chan ;

Christine I. Chen ;

Donna E. Reece .

Current Hematologic Malignancy Reports, 2017, 12 :96-108

[26] Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma [J].

Bumma, Naresh ;

Dhakal, Binod ;

Fraser, Raphael ;

Estrada-Merly, Noel ;

Anderson, Kenneth ;

Freytes, Cesar O. ;

Hildebrandt, Gerhard C. ;

Holmberg, Leona ;

Krem, Maxwell M. ;

Lee, Cindy ;

Lekakis, Lazaros ;

Lazarus, Hillard M. ;

Mian, Hira ;

Murthy, Hemant S. ;

Nathan, Sunita ;

Nishihori, Taiga ;

Parrondo, Ricardo ;

Patel, Sagar S. ;

Solh, Melhem ;

Strouse, Christopher ;

Vesole, David H. ;

Kumar, Shaji ;

Qazilbash, Muzaffar H. ;

Shah, Nina ;

D'Souza, Anita ;

Sidana, Surbhi .

CANCER, 2023, 129 (14) :2179-2191

[27] The efficacy of new drug regimens in treating newly diagnosed high-risk cytogenetic multiple myeloma patients: a systematic literature review and meta-analysis [J].

Zhou, Huixing ;

Chen, Wenming .

FRONTIERS IN MEDICINE, 2025, 12

[28] Approach to High-Risk Multiple Myeloma [J].

Chen, Xiaoyi ;

Varma, Gaurav ;

Davies, Faith ;

Morgan, Gareth .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 38 (02) :497-510

[29] A gene expression signature for high-risk multiple myeloma [J].

R Kuiper ;

A Broyl ;

Y de Knegt ;

M H van Vliet ;

E H van Beers ;

B van der Holt ;

L el Jarari ;

G Mulligan ;

W Gregory ;

G Morgan ;

H Goldschmidt ;

H M Lokhorst ;

M van Duin ;

P Sonneveld .

Leukemia, 2012, 26 :2406-2413

[30] Management of high-risk Myeloma: an evidence-based review of treatment strategies [J].

Lehners, Nicola ;

Hayden, Patrick J. ;

Goldschmidt, Hartmut ;

Raab, Marc-Steffen .

EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (08) :753-765

← 1 2 3 4 5 →